Articoli con mandati relativi all'accesso pubblico - Matcheri KeshavanUlteriori informazioni
Non disponibili pubblicamente: 77
Schizophrenia,“just the facts”: What we know in 2008: Part 3: Neurobiology
MS Keshavan, R Tandon, NN Boutros, HA Nasrallah
Schizophrenia research 106 (2-3), 89-107, 2008
Mandati: US National Institutes of Health
Brain structure and symptom dimension relationships in obsessive–compulsive disorder: a voxel-based morphometry study
AR Gilbert, D Mataix-Cols, JRC Almeida, N Lawrence, J Nutche, ...
Journal of affective disorders 109 (1-2), 117-126, 2008
Mandati: US National Institutes of Health
Reimagining psychoses: an agnostic approach to diagnosis
MS Keshavan, BA Clementz, GD Pearlson, JA Sweeney, CA Tamminga
Schizophrenia research 146 (1-3), 10-16, 2013
Mandati: US National Institutes of Health
Treatment to enhance cognition in bipolar disorder (TREC-BD): efficacy of a randomized controlled trial of cognitive remediation versus active control
KE Lewandowski, SH Sperry, BM Cohen, LA Norris, GM Fitzmaurice, ...
The Journal of clinical psychiatry 78 (9), 3199, 2017
Mandati: US National Institutes of Health
Strategies for advancing disease definition using biomarkers and genetics: the bipolar and schizophrenia network for intermediate phenotypes
CA Tamminga, GD Pearlson, AD Stan, RD Gibbons, J Padmanabhan, ...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 2 (1), 20-27, 2017
Mandati: US National Institutes of Health
Neural correlates of cognitive deficits across developmental phases of schizophrenia
S Kelly, S Guimond, A Lyall, WS Stone, ME Shenton, M Keshavan, ...
Neurobiology of disease 131, 104353, 2019
Mandati: US National Institutes of Health
Serum vitamin D and hippocampal gray matter volume in schizophrenia
V Shivakumar, SV Kalmady, AC Amaresha, D Jose, JC Narayanaswamy, ...
Psychiatry Research: Neuroimaging 233 (2), 175-179, 2015
Mandati: Department of Biotechnology, India, Department of Science & Technology …
A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy
LF Jarskog, MT Lowy, RA Grove, RSE Keefe, JP Horrigan, MP Ball, ...
Schizophrenia research 164 (1-3), 136-142, 2015
Mandati: US National Institutes of Health, National Medical Research Council, Singapore
Longitudinal functional brain imaging study in early course schizophrenia before and after cognitive enhancement therapy
MS Keshavan, SM Eack, KM Prasad, CS Haller, RY Cho
Neuroimage 151, 55-64, 2017
Mandati: US National Institutes of Health
Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis
DC D’Souza, M DiForti, S Ganesh, TP George, W Hall, C Hjorthøj, ...
The World Journal of Biological Psychiatry 23 (10), 719-742, 2022
Mandati: US National Institutes of Health, Canadian Institutes of Health Research
Is cognitive enhancement therapy equally effective for patients with schizophrenia and schizoaffective disorder?
KE Lewandowski, SM Eack, SS Hogarty, DP Greenwald, MS Keshavan
Schizophrenia Research 125 (2-3), 291-294, 2011
Mandati: US National Institutes of Health
Resting-state functional connectivity predictors of treatment response in schizophrenia–A systematic review and meta-analysis
UM Mehta, FA Ibrahim, MS Sharma, G Venkatasubramanian, J Thirthalli, ...
Schizophrenia Research 237, 153-165, 2021
Mandati: US National Institutes of Health, Department of Biotechnology, India …
Testing psychosis phenotypes from bipolar–schizophrenia network for intermediate phenotypes for clinical application: biotype characteristics and targets
BA Clementz, RL Trotti, GD Pearlson, MS Keshavan, ES Gershon, ...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 5 (8), 808-818, 2020
Mandati: US National Institutes of Health
Inefficiently increased anterior cingulate modulation of cortical systems during working memory in young offspring of schizophrenia patients
N Bakshi, P Pruitt, J Radwan, MS Keshavan, U Rajan, C Zajac-Benitez, ...
Journal of psychiatric research 45 (8), 1067-1076, 2011
Mandati: US National Institutes of Health
Characterizing functional regional homogeneity (ReHo) as a B-SNIP psychosis biomarker using traditional and machine learning approaches
L Ji, SA Meda, CA Tamminga, BA Clementz, MS Keshavan, JA Sweeney, ...
Schizophrenia research 215, 430-438, 2020
Mandati: US National Institutes of Health
Similar and contrasting dimensions of social cognition in schizophrenia and healthy subjects
UM Mehta, J Thirthalli, HD Bhagyavathi, JK Kumar, DK Subbakrishna, ...
Schizophrenia research 157 (1-3), 70-77, 2014
Mandati: Department of Biotechnology, India
Cognitive dysfunction in a psychotropic medication-naïve, clinical high-risk sample from the ShangHai-At-Risk-for-Psychosis (SHARP) study: associations with clinical outcomes
H Cui, AJ Giuliano, T Zhang, L Xu, Y Wei, Y Tang, Z Qian, LM Stone, H Li, ...
Schizophrenia Research 226, 138-146, 2020
Mandati: US National Institutes of Health, National Natural Science Foundation of China
Reduced activation of superior temporal gyrus during auditory comprehension in young offspring of patients with schizophrenia
R Rajarethinam, BK Venkatesh, R Peethala, KL Phan, M Keshavan
Schizophrenia research 130 (1-3), 101-105, 2011
Mandati: US National Institutes of Health
Machine learning improved classification of psychoses using clinical and biological stratification: update from the bipolar-schizophrenia network for intermediate phenotypes (B …
SS Mothi, M Sudarshan, N Tandon, C Tamminga, G Pearlson, J Sweeney, ...
Schizophrenia research 214, 60-69, 2019
Mandati: US National Institutes of Health
Investigating sleep spindle density and schizophrenia: A meta-analysis
M Lai, R Hegde, S Kelly, D Bannai, P Lizano, R Stickgold, DS Manoach, ...
Psychiatry Research 307, 114265, 2022
Mandati: US National Institutes of Health
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software